Patient characteristics | All patients n = 104 (%) |
---|---|
Sex | |
Male | 76 (73) |
Female | 28 (27) |
Median age ± SD (years) | 66 ± 10.2 |
Treatment arm | |
IT-RT | 50 (48) |
IT-only | 54 (52) |
Location of radiotherapya (n = 50) | |
Lung | 17 (34) |
CNS | 10 (20) |
Bone | 5 (10) |
Other | 18 (36) |
PD-L1 tumor cells | |
< 1% | 36 (35) |
1–49% | 33 (32) |
≥ 50% | 32 (31) |
Unknown | 3 (3) |
Brain metastases | 24 (23) |
Tumor entity | |
NSCLC | 46 (44) |
HNSCC | 44 (42) |
Bladder cancer | 5 (5) |
Oesophageal cancer | 4 (4) |
Other | 5 (5) |
Number of previous treatments | |
0–1 | 61 (59) |
≥ 2 | 43 (41) |
Disease stage | |
Adjuvant setting | 12 (12) |
Palliative setting | 92 (88) |
local tumor recurrence | 15 (14) |
distant metastases | 77 (74) |
Drug | |
Nivolumab | 66 (64) |
Pembrolizumab | 24 (23) |
Durvalumab | 9 (9) |
Other | 5 (5) |
Concomitant chemotherapy | 6 (6) |
Comorbidityb (n = 199) | |
Arterial hypertonia | 34 (33) |
Cardiovascular comorbidity | 30 (29) |
Diabetes | 20 (19) |
COPD | 18 (17) |
Autoimmune disease | 2 (2) |
Other | 87 (84) |
None | 8 (8) |